Biocon Settles With Genentech, Locking In 2027 Europe and 2028 US Launch Windows for Its Perjeta Biosimilar

For a biosimilar maker, getting a molecule approved is only half the job. The other half is getting past the originator's patents. On 14 October, Biocon told the stock exchanges that it had settled with Genentech on Pebrilzo, its biosimilar of Genentech's breast-cancer antibody Perjeta (pertuzumab). The global settlement and licence agreement ends the patent disputes between the two companies and gives Biocon licensed launch dates across major markets.

What the settlement says

Under the agreement, Biocon may launch Pebrilzo in the European Union and the United Kingdom from the first quarter of calendar 2027, and in the United States from the third quarter of 2028. In other markets, launch dates fall between 2026 and 2028, or earlier in certain circumstances, subject to conditions. According to the company's filing and reports from BioSpectrum, Medical Dialogues and DSIJ, the deal resolves pending litigation in the US, Canada and other jurisdictions. Financial and other terms are confidential.

Biocon called these the "earliest licensed launch dates" for the product. The dates are permissions from the patent holder, not regulatory approvals: each launch still needs clearance from the regulator in that market. The stock market reaction was muted, with HDFC Sky reporting that Biocon shares fell 0.94% on the day.

The regulatory backdrop

The settlement comes weeks after a notable regulatory step. In September, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending Pebrilzo for approval. Biocon said it was the first monoclonal-antibody biosimilar to receive a positive CHMP opinion under the EMA's new "tailored clinical approach".

That approach matters to the economics of biosimilars. Traditionally, biosimilar developers had to run large, expensive comparative efficacy trials in patients. The tailored approach relies instead on extensive structural and functional analysis, plus comparative pharmacokinetic data, to show that the biosimilar behaves like the reference product. As the law firm Goodwin noted in its review, Pebrilzo was evaluated this way. That makes Biocon's product an early test case for a cheaper route to market that regulators are increasingly willing to accept.

The CHMP opinion covers a 420 mg concentrate for infusion. It is recommended with trastuzumab and chemotherapy before and after surgery for high-risk HER2-positive early breast cancer, and with trastuzumab and docetaxel for metastatic or locally recurrent, unresectable HER2-positive breast cancer in patients who have not had prior anti-HER2 therapy or chemotherapy for metastatic disease. The European Commission's final decision is still pending, and the product is not yet approved by the US FDA.

Why pertuzumab matters

Pertuzumab is a monoclonal antibody that binds the HER2 receptor at a different site from trastuzumab, blocking it from pairing with other receptors in the same family. The two antibodies are usually given together in HER2-positive breast cancer, a subtype that makes up a significant share of breast-cancer cases worldwide. The originator drug is expensive, and in many countries cost limits how many patients receive it. Biosimilar competition is the standard way to bring prices down.

Biocon will not be alone. BioPharm International noted that Pebrilzo would not be the first pertuzumab biosimilar to reach the EU market. So timing and pricing will matter. The settlement gives Biocon legal certainty on when it can enter, which is often worth more than winning a patent case years later.

Why settle rather than fight

Settlements like this are common in biologics. Originator companies usually protect a blockbuster antibody with many patents covering the molecule, formulation, manufacturing process and dosing. Biosimilar makers can challenge them one by one, but litigation in several countries is slow, expensive and uncertain. A licensed entry date lets the biosimilar maker plan manufacturing, supply contracts and launches with confidence. The originator, in turn, gets a predictable timeline for when competition starts. In the US, for example, biosimilars of AbbVie's Humira entered the market in 2023 under dates set in earlier patent settlements.

For Biocon, the gap between the EU/UK window (Q1 2027) and the US window (Q3 2028) suggests a staged rollout. Europe, with its well-developed biosimilar market and tender-based purchasing, comes first, followed by the larger but more litigious US market.

The India angle

Biocon is one of the few Indian companies that develops complex biologics in-house and sells them in regulated Western markets, where scrutiny is heaviest. Its antibody biosimilars, such as trastuzumab and bevacizumab, built that position, and pertuzumab extends the portfolio in oncology. Developing a monoclonal-antibody biosimilar requires cell-line development, large-scale bioreactor manufacturing, detailed analytical characterisation and years of regulatory work. These are deep-tech capabilities that India's broader biotech push, including the government's BioE3 biomanufacturing policy, is trying to spread across more companies.

A first-of-its-kind CHMP opinion under the tailored pathway also has value beyond Biocon. It shows that an Indian developer's analytical data can carry much of the weight of a regulatory submission in Europe. That could encourage other Indian biosimilar makers to invest in analytical science rather than costly large trials.

What comes next

Three things to watch:

• European Commission approval, which typically follows a positive CHMP opinion, and is needed before the Q1 2027 EU/UK launch window.
• US regulatory progress ahead of the Q3 2028 licensed entry date.
• Earlier launches in other markets during 2026–2028, where the licence allows entry sooner.

For now, Biocon has cleared the legal path for one of its most important upcoming oncology biosimilars. Regulators and the market will decide the rest.

Sources

• https://nsearchives.nseindia.com/corporate/BIOCON_14102026082951_SEIntimation.pdf
• https://biospectrumindia.com/news/95/28646/biocon-secures-earliest-licensed-launch-dates-for-pebrilzo-bpertuzumab-following-global-patent-settlement-with-genentech.html
• https://medicaldialogues.in/news/industry/pharma/biocon-secures-global-patent-settlement-with-genentech-sets-2027-eu-launch-for-perjeta-biosimilar-181307
• https://insights.dsij.in/dsijarticledetail/biocon-settles-genentech-disputes-secures-2027-eu-and-2028-us-launch-window-for-pebrilzo-id022
• https://hdfcsky.com/news/biocon-secures-pebrilzo-launch-dates-shares-fall-0-94-percent
• https://www.goodwinlaw.com/en/insights/blogs/2026/10/biocons-pertuzumab-biosimilar-receives-positive-chmp-opinion-under-emas-tailored-clinical-approach
• https://medicaldialogues.in/news/industry/pharma/biocon-gets-positive-chmp-opinion-for-pertuzumab-biosimilar-pebrilzo-in-her2-positive-breast-cancer-179713
• https://www.biopharminternational.com/view/biocon-s-pertuzumab-biosimilar-earns-chmp-nod-under-ema-s-new-tailored-pathway